Literature DB >> 22056881

MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo.

X-X He1, Y Chang, F-Y Meng, M-Y Wang, Q-H Xie, F Tang, P-Y Li, Y-H Song, J-S Lin.   

Abstract

MicroRNAs (miRNAs) are believed to have fundamental roles in tumorigenesis and have great potential for the diagnosis and treatment of cancer. However, the roles of miRNAs in hepatocellular carcinogenesis are still not fully elucidated. We investigated the aberrantly expressed miRNAs involved in hepatoma by comparison of miRNA expression profiles in cancerous hepatocytes with normal primary human hepatocytes, and 37 dysregulated miRNAs were screened out by twofold change with a significant difference (P<0.05). Clustering analysis based on 13 miRNAs with changes over 15-folds showed that the miRNA expression patterns between the cancerous and normal hepatocytes were clearly different. Among the 13 miRNAs, we found that miR-375 was significantly downregulated in hepatocellular carcinoma (HCC) tissues and cell lines. Overexpression of miR-375 in liver cancer cells decreased cell proliferation, clonogenicity, migration/invasion and also induced G1 arrest and apoptosis. To unveil the molecular mechanism of miR-375-mediated phenotype in hepatoma cells described above, we examined the putative targets using bioinformatics tools and found that astrocyte elevated gene-1 (AEG-1) was a potential target of miR-375. Then we demonstrated that miR-375 bound directly to the 3'-untranslated region of AEG-1 and inhibited the expression of AEG-1. TaqMan quantitative reverse transcriptase-PCR and western blot analysis showed that miR-375 expression was inversely correlated with AEG-1 expression in HCC tissues. Knockdown of AEG-1 by RNAi in HCC cells, similar to miR-375 overexpression, suppressed tumor properties. Ectopic expression of AEG-1, conversely, could partially reverse the antitumor effects of miR-375. In a mouse model, therapeutic administration of cholesterol-conjugated 2'-O-methyl-modified miR-375 mimics (Chol-miR-375) could significantly suppress the growth of hepatoma xenografts in nude mice. In conclusion, our findings indicate that miR-375 targets AEG-1 in HCC and suppresses liver cancer cell growth in vitro and in vivo, and highlight the therapeutic potential of miR-375 in HCC treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22056881     DOI: 10.1038/onc.2011.500

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  157 in total

1.  High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21-Mediated Matrix Metalloproteinase Activity.

Authors:  Man Chen; Yao Liu; Patrick Varley; Ying Chang; Xing-Xing He; Hai Huang; Daolin Tang; Michael T Lotze; Jusheng Lin; Allan Tsung
Journal:  Cancer Res       Date:  2015-02-26       Impact factor: 12.701

2.  MiR-98 inhibits malignant progression via targeting MTDH in squamous cell carcinoma of the head and neck.

Authors:  Haolei Tan; Gangcai Zhu; Li She; Ming Wei; Yunyun Wang; Leiming Pi; Changhan Chen; Diekuo Zhang; Pingqing Tan; Jie Chen; Donghai Huang; Yongquan Tian; Yong Liu; Xin Zhang
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

3.  MicroRNA-216b is Down-Regulated in Human Gastric Adenocarcinoma and Inhibits Proliferation and Cell Cycle Progression by Targeting Oncogene HDAC8.

Authors:  Ying Wang; Po Xu; Jun Yao; Ruina Yang; Zhenguo Shi; Xiaojuan Zhu; Xiaoshan Feng; Shegan Gao
Journal:  Target Oncol       Date:  2016-04       Impact factor: 4.493

4.  CP-31398 prevents the growth of p53-mutated colorectal cancer cells in vitro and in vivo.

Authors:  Xingxing He; Xinjuan Kong; Junwei Yan; Jingjun Yan; Yunan Zhang; Qian Wu; Ying Chang; Haitao Shang; Qian Dou; Yuhu Song; Fang Liu
Journal:  Tumour Biol       Date:  2015-02-08

Review 5.  The role of microRNAs in hepatocarcinogenesis: current knowledge and future prospects.

Authors:  Motoyuki Otsuka; Takahiro Kishikawa; Takeshi Yoshikawa; Motoko Ohno; Akemi Takata; Chikako Shibata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2013-11-21       Impact factor: 7.527

Review 6.  In vivo delivery of miRNAs for cancer therapy: challenges and strategies.

Authors:  Yunching Chen; Dong-Yu Gao; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2014-05-22       Impact factor: 15.470

7.  Astrocyte elevated gene-1 and c-Myc cooperate to promote hepatocarcinogenesis in mice.

Authors:  Jyoti Srivastava; Ayesha Siddiq; Rachel Gredler; Xue-Ning Shen; Devaraja Rajasekaran; Chadia L Robertson; Mark A Subler; Jolene J Windle; Catherine I Dumur; Nitai D Mukhopadhyay; Dawn Garcia; Zhao Lai; Yidong Chen; Uthra Balaji; Paul B Fisher; Devanand Sarkar
Journal:  Hepatology       Date:  2015-01-23       Impact factor: 17.425

8.  AU-binding factor 1 expression was correlated with metadherin expression and progression of hepatocellular carcinoma.

Authors:  Yingzhuo Yang; Peng Kang; Jie Gao; Chunlin Xu; Shimei Wang; Haiyu Jin; Yunling Li; Wenjuan Liu; Xia Wu
Journal:  Tumour Biol       Date:  2013-11-09

9.  An integrative bioinformatics analysis identified miR-375 as a candidate key regulator of malignant breast cancer.

Authors:  Jiaxuan Liu; Ping Wang; Ping Zhang; Xinyu Zhang; Hang Du; Qiang Liu; Bo Huang; Caiyun Qian; Shuhua Zhang; Weifeng Zhu; Xiaohong Yang; Yingqun Xiao; Zhuoqi Liu; Daya Luo
Journal:  J Appl Genet       Date:  2019-08-01       Impact factor: 3.240

10.  Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma.

Authors:  Matthias Dettmer; Aurel Perren; Holger Moch; Paul Komminoth; Yuri E Nikiforov; Marina N Nikiforova
Journal:  Thyroid       Date:  2013-09-19       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.